North America Glioma Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The North America glioma market was valued at USD 1.03 Billion in 2025. It is expected to grow at a CAGR of 3.22% during the forecast period of 2026-2035, reaching USD 1.41 Billion by 2035. The market is driven by the rising incidence of brain tumors in the region, growing regulatory approvals of innovative glioma therapies, and increasing adoption of advanced diagnostic techniques.

Latest News on the North America Glioma Market (2026)

• According to the American Society of Clinical Oncology (ASCO), approximately 24,820 adults are expected to be diagnosed with primary cancerous brain and spinal cord tumors in the United States annually, driving demand for advanced glioma treatment options.
• In August 2024, the United States Food and Drug Administration (FDA) accepted and granted priority review to Servier Pharmaceuticals' vorasidenib, a novel dual inhibitor targeting IDH-mutant glioma, expanding the treatment pipeline.
• The key market players play a crucial role by investing in research and development, expanding therapeutic pipelines, improving diagnostic solutions, and forming strategic collaborations, thereby accelerating innovation, enhancing treatment accessibility, and supporting overall market growth.

According to the American Society of Clinical Oncology (ASCO), approximately 24,820 adults are expected to be diagnosed with primary cancerous brain and spinal cord tumors in the United States annually, driving demand for advanced glioma treatment options.

In August 2024, the United States Food and Drug Administration (FDA) accepted and granted priority review to Servier Pharmaceuticals' vorasidenib, a novel dual inhibitor targeting IDH-mutant glioma, expanding the treatment pipeline.

The key market players play a crucial role by investing in research and development, expanding therapeutic pipelines, improving diagnostic solutions, and forming strategic collaborations, thereby accelerating innovation, enhancing treatment accessibility, and supporting overall market growth.

Key Market Trends and Insights

• By type, the glioblastoma segment likely accounted for approximately 45% of the market share in the historical period.
• By diagnosis, the magnetic resonance imaging (MRI) segment is expected to lead the market in the forecast period.
• By treatment type, the chemotherapy segment is anticipated to dominate the market in the historical period.

Market Size and Forecast

• Market Size (2025): USD 1.03 Billion
• Projected Market Size (2035): USD 1.41 Billion
• CAGR (2026-2035): 3.22%

North America Glioma Market Overview

Glioma is a primary brain tumor originating from glial cells, encompassing subtypes such as astrocytoma, oligodendroglioma, and glioblastoma multiforme. As per the analyst, the market was valued at USD 1.03 Billion in 2025. The region holds a dominant position due to its advanced healthcare infrastructure, high research and development investment, and strong regulatory frameworks that accelerate the approval of new therapies. Diagnostic advancements, including magnetic resonance imaging (MRI) and molecular profiling, and the rising adoption of temozolomide chemotherapy and radiation therapy are collectively shaping the region's market landscape.

North America Glioma Market Growth Drivers

Rising Incidence of Glioblastoma to Fuel the Market Demand

The escalating burden of glioblastoma multiforme and other high-grade brain tumors is a primary driver of the market. According to Quinn T Ostrom et al., 2023, gliomas accounted for 26.3% of all primary brain and central nervous system tumors, with glioblastoma representing the most common malignant subtype. The substantial mortality and low survival rates associated with these tumors emphasize the urgent need for advanced therapies, thereby accelerating research, innovation, and overall market expansion.

North America Glioma Market Growth Trends

The key trends in the market include an increase in regulatory approvals, driving faster commercialization of novel therapies and improving patient access to advanced neuro-oncology treatments.

Growing Regulatory Approvals to Accelerate the Market Landscape

The surge in regulatory approvals of novel, targeted glioma treatment agents, is a key trend shaping the market. In February 2024, the FDA granted priority review to vorasidenib, a dual IDH-mutant glioma inhibitor developed by Servier Pharmaceuticals, based on positive Phase 3 INDIGO trial findings, marking a significant step in precision oncology for diffuse glioma. Additionally, in April 2024, the FDA approved OJEMDA (tovorafenib) for relapsed or refractory BRAF-altered pediatric low-grade glioma, representing the first approval for this molecular subtype. These approvals are among the key trends driving the market.

North America Glioma Market Segmentation

Market Breakup by Type

• Astrocytoma
• Oligodendroglioma
• Glioblastoma

Market Breakup by Diagnosis

• Angiograms
• Magnetic Resonance Imaging (MRI)
• Computerized Tomography (CT)
• Surgical Biopsy
• Others

Market Breakup by Treatment Type

• Chemotherapy
• Radiation
• Surgery

Market Breakup by Route of Administration

• Oral
• Parenteral

Market Breakup by Country

• United States
• Canada

North America Glioma Market Share

Glioblastoma Segment Expected to Lead the Market Share by Type

The glioblastoma segment is likely to hold a significant share in the market by type, owing to its status as the most prevalent and aggressive form of primary brain tumor. Its high recurrence rate and limited treatment response drive significant and sustained clinical expenditure on chemotherapy protocols, including temozolomide, radiation therapy, and surgical resection, reinforcing the segment's continued market leadership through the forecast period.

North America Glioma Market Analysis by Region

The regions included in the market are the United States and Canada. Among these, the United States is anticipated to hold a substantial share in the market, supported by advanced glioma diagnosis infrastructure, high R&D investment, and a robust pipeline of novel brain cancer treatment agents. Canada also contributes significantly to the regional market, driven by a large number of glioblastoma diagnoses and growing public investment in neuro-oncology research.

Leading Players in the North America Glioma Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Pfizer Inc.

Pfizer Inc. is a global pharmaceutical leader headquartered in New York, United States. The company maintains an active oncology pipeline with research in brain tumors treatment and neurological conditions. Pfizer leverages its strong R&D capabilities, broad clinical trial network, and global commercialization infrastructure to develop and deliver targeted therapies addressing high unmet needs in neuro-oncology, including glioblastoma multiforme.

Novartis AG

Novartis AG is a Switzerland-based multinational pharmaceutical company with a significant presence in oncology. The company invests extensively in glioma treatment research, pursuing targeted molecular therapies and combination regimens for brain cancer. Novartis's established regulatory expertise, global manufacturing capabilities, and strong clinical development programs position it as a key contributor to the North America glioma treatment landscape.

Johnson & Johnson

Johnson and Johnson is a diversified healthcare conglomerate headquartered in the United States. Through its Janssen Pharmaceuticals division, the company focuses on oncology innovation, including research into brain tumor therapy and neuro-oncology solutions. Its integrated approach combining pharmaceuticals, medical devices, and diagnostics supports a broad strategy for advancing glioma diagnosis and treatment across North American healthcare systems.

Merck & Co., Inc.

Merck & Co Inc. is a United States-based science and technology company with significant oncology expertise. The company leverages strategic collaborations and pipeline development to accelerate the market entry of novel brain cancer treatment candidates, including those targeting IDH-mutant glioma. Merck's prescription product portfolio and commitment to immunotherapy research reinforce its position in the North America glioma market.

Other players in the market include Roche Holding AG, Bristol-Myers Squibb Company, Amgen Inc., AstraZeneca PLC, AbbVie Inc., and Eli Lilly and Company.

Key Questions Answered in the North America Glioma Market Report

• What was the North America glioma market value in 2025?
• What is the North America glioma market forecast outlook for 2026-2035?
• What major factors aid the demand for the North America glioma market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major North America glioma market trends?
• Which drug class is expected to dominate the market segment?
• Which formulation is projected to lead the market segment?
• Which packaging type is anticipated to drive the market segment?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players in the North America glioma market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?